EUCTR2008-000342-32-DE进行中（未招募）不适用
An open-label, flexible dose, follow-up study to evaluate safety andefficacy of oral pramipexole (0.0625-0.5 mg/day) for 24 weeks inchildren and adolescents (age 6-17 years) diagnosed with TouretteSyndrome according to DSM-IV criteria and who have completed thedouble-blind phase of either study 248.641 or 248.644
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients aged 6-17 years at the time of enrollment into study 248.641 or 248.644 and who have completed study 248.641 or 248.644.
- •2. Written informed consent provided by the patient’s parent (or legal guardian) and
- •assent provided by the patient consistent with ICH GCP and local Institutional
- •Review Board (IRB) requirements for children obtained prior to any study procedures
- •being performed.
- •3. Ability and willingness to comply with study treatment regimen and to complete
- •study assessments.
- •4. Females of childbearing potential having a negative serum ß-HCG pregnancy test at Visit 1.
- •5. Females of childbearing potential must be using a medically accepted contraceptive
- •method throughout the study. Acceptable methods of birth control are limited to:
- •Intra-Uterine Device (IUD), oral, implantable, injectable contraceptives or estrogen
- •patch, double barrier method (spermacide + diaphragm), or abstinence at the
- •discretion of the investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Breastfeeding females.
- •2. Development of any clinical condition in the preceding trial that in the investigator’s
- •opinion could be worsened by treatment with pramipexole.
- •3. Clinically significant renal disease or serum creatinine out of this range:
- •0.3-1.0 mg/dL for patients aged 6-12 years and 0.5-1.4 mg/dL for patients aged 13+ years.
- •4. Any of the following lab results at screening:
- •- Hemoglobin (Hgb) below lower limit of normal (LLN) which is determined to be clinically significant
- •- Basal thyroid stimulating hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significant (at the investigator’s discretion) out of normal range at screening (if not caused by substitution therapy according the investigator’s opinion)
- •- Patients with any clinically significant abnormalities in laboratory parameters at screening at the investigator’s discretion.
- •5. Other clinically significant metabolic-endocrine, hematological, gastrointestinal disease, or pulmonary disease (such as severe asthma) in the opinion of the
- •investigator that would preclude the patient from participating in this study.
- •6. History or presence of schizophrenia or any psychotic disorder. History or presence of any psychiatric disorder requiring medical therapy with the exception for patients with a diagnosis of TS, ADHD or OCD who are not on therapy other than pramipexole.
- •7. History or presence of clinical signs of epilepsy or seizures other than fever-related
- •seizures in early childhood.
- •8. History or presence of clinical signs of any malignant neoplasm including suspicious
- •undiagnosed skin lesion (which may be melanoma), melanoma, or a history of
- •9. History of any other medical treatment for TS besides the study medication within
- •28 days prior to the baseline visit (14 days prior to baseline for guanfacine and clonidine, 14 days prior to baseline for dopamine agonists, 14 days prior to baseline for L-Dopa, 35 days prior to baseline for fluoxetine).
- •10. Patients receiving psychotherapy are excluded unless they started the treatment at least 3 months prior to starting the trial and no changes in treatment are planned for the duration of the study.
- •11. Allergic response to pramipexole or the inactive ingredients in its tablet formulation.
- •12. Non-compliance with study medication (defined as less than 80% or more than 120%) during the preceding Study 248.641 or 248.644.
- •13. Concurrent participation in another clinical trial using any investigational drug since completion of the preceding Study 248.641 or 248.644.
- •14. Any other conditions, that in the opinion of the investigator, would interfere with the evaluation of the results or constitute a health hazard for the patient.
研究者
相似试验
进行中（未招募）
不适用
An open-label, flexible dose, follow-up study to evaluate safety and effectiveness of oral pramipexole (0.0625 – 0.5mg/day) for 24-weeks in children and adolescents (age 6-17 years) who have been diagnosed with Tourette Syndrome and who have completed the previous trials 248.641 or 248.644Tourette's SyndromeMedDRA version: 14.0Level: LLTClassification code 10044127Term: Tourette's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-000342-32-Outside-EU/EEABoehringer Ingelheim Pharmaceuticals, Inc.120
进行中（未招募）
1 期
Study With Vortioxetine on Emotional Functioning in Patients With DepressioEUCTR2017-004829-33-ITH. LUNDBECK A/S150
进行中（未招募）
1 期
Study With Vortioxetine on Emotional Functioning in Patients With DepressioEmotional functioning in patients with MDDMedDRA version: 20.0Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-004829-33-FRH. Lundbeck A/S150
进行中（未招募）
1 期
Study With Vortioxetine on Emotional Functioning in Patients With DepressioEUCTR2017-004829-33-LTH. Lundbeck A/S150
进行中（未招募）
1 期
Study With Vortioxetine on Emotional Functioning in Patients With DepressioEUCTR2017-004829-33-ESH. Lundbeck A/S151